Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutically, additional and more specific LMP1 and Capn4 targeted inhibitors could be exploited to treat NPC.
|
31691433 |
2020 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fibronectin is regarded as a prognosticator in NPC and its involvement in cell motility has been reported in EBV infection and viral latent membrane protein 1 (LMP1) overexpression NPC cell lines.
|
30551431 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The study revealed that aspirin is a promising drug for NPC therapy via its targeting of exo-LMP1 transfer and the regulatory effect of LMP1 on miR-203 expression.
|
31265948 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we found that LMP1-positive EVs could promote tumor growth and P38 inhibition eliminates this promoting effect in vivo, and EV formation is associated with a poor prognosis in NPC patients.
|
31436393 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of γ-H2AX, latent membrane protein 1 (LMP1), and EBV-encoded RNA in clinical NPC and nasopharyngeal inflammation (NPI) specimens were examined using immunohistochemistry and in situ hybridization.
|
30666155 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Despite monoclonal infection in cases of nasopharyngeal carcinoma (NPC), it has been difficult to reconcile the heterogeneous LMP1 protein levels detected in tumor cells.
|
29134204 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, the results revealed a significant association of p53-positive status with a poor 5-year survival of nasopharyngeal carcinoma (NPC) patients as the risk difference (RD) was -0.17 (95% CI, -0.31, -0.03; P=0.02, Pheterogeneity =0.01).The overall odds ratio (OR) for LMP1 in the p53 positive group vs. negative group revealed that a significantly elevated risk of positive LMP1 in the former was achieved (OR 5.52 95% CI, 2.66-11.46; P<0.00001, Pheterogeneity =0.78).
|
30063067 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The LMP1 stable expression cell line CNE1-LMP1-OV was constructed through infecting the well-differentiated nasopharyngeal carcinoma cells CNE1 with LMP1 overexpressing lentivirus.
|
30809095 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of LMP1 and Cripto-1 in nasopharyngeal carcinoma is positively related.
|
31375471 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMP1 DNA and EBER1 RNA correlated with the metastasis of nasopharyngeal carcinoma.
|
31832991 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study highlights the functional importance of IGF1-mTORC2-PDHE1α signaling mediated by EBV-LMP1 in NPC pathogenesis.
|
30745576 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human NPC CNE-2 cells were infected with the recombinant LMP1- and LMP2A-carrying lentivirus, and then examined for cell growth with the colony forming assay as well as for the activation of transcription of eukaryotic translation initiation factor 4E (eIF4E) with reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) and western blot.
|
31673282 |
2019 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The EBV-encoded latent membrane protein 1 (LMP1), which is commonly expressed in NPC, engages multiple signaling pathways that promote cell growth, transformation, and metabolic reprogramming.
|
29968360 |
2018 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the occurrence and significance of VM in NPC and the relationship between LMP1 and VM have not yet been evaluated.
|
29749553 |
2018 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (EBV-LMP1) is closely associated with nasopharyngeal carcinoma (NPC) pathogenesis because it can trigger multiple cell signaling pathways that promote cell transformation, proliferation, immune escape, invasiveness, epigenetic modification, and metabolic reprogramming.
|
29795311 |
2018 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of LMP1 promoted the outgrowth of the NPC cell line HK1 following anoikis induction that was not attributed to enhanced cell survival in suspension or reattachment.
|
29950426 |
2018 |
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data suggest new functions of the N terminus and transmembrane domains in LMP1 intra- and extracellular trafficking that are likely downstream of an interaction with CD63.<b>IMPORTANCE</b> EBV infection contributes to the development of cancers, such as nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin's disease, and posttransplant lymphomas, in immunocompromised or genetically susceptible individuals.
|
29950415 |
2018 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will discuss the significance of recent advances in NPC research from elucidating LMP1 function in epithelial cells and lessons that could be learned from mining LMP1 sequence diversity.
|
29561768 |
2018 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent studies suggest that LMP1 activity shifts according to tumor development stage, but it still has a pivotal role during all stages of NPC development.
|
29247573 |
2018 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we reported that TAZ was frequently expressed in LMP1-positive nasopharyngeal carcinoma.
|
28881733 |
2017 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NF-κB activation is involved in the LMP1-induced upregulation of glucose transporter 1 (Glut-1) transcription and growth of nasopharyngeal carcinoma (NPC) cells.
|
28053105 |
2017 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epstein-Barr virus latent membrane protein 1 (LMP1) is expressed in multiple human malignancies, including nasopharyngeal carcinoma and Hodgkin and immunosuppression-associated lymphomas.
|
28835489 |
2017 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Latent membrane protein 1 (LMP1), an oncogenic protein, plays an important role in malignant transformation in EBV-associated nasopharyngeal carcinoma and B-cell lymphoma; however, its expression has not been detected in EBV-associated gastric cancer.
|
28454117 |
2017 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Latent membrane protein 1 (LMP1) is a principal viral oncoprotein in Epstein-Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC), which acts through regulating tumorigenesis and metabolic reprogramming of cancers.
|
28827059 |
2017 |
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that EBV infection or ectopic expression of the EBV-encoded latent genes (EBNA1, LMP1, and LMP2A) can up-regulate sphingosine kinase 1 (SPHK1), the key enzyme that produces S1P, in NPC cell lines.
|
28240350 |
2017 |